Electrocardiography in Early Diagnosis of Cardiovascular Complications of COVID-19; a Systematic Literature Review

Reza Nemati1, Mahasty Ganjoo1, Faezeh Jadidi2, Ahmad Tanha3, Reza Baghbani1*

1. Department of Medical Emergencies, School of Allied Medical Sciences, Bushehr University of Medical Sciences, Bushehr, Iran.
2. Student Research Committee, Zarand School of Nursing, Kerman University of Medical Sciences, Kerman, Iran.
3. Clinical Research Development Center, The Persian Gulf Martyrs Hospital, Bushehr University of Medical Sciences, Bushehr, Iran.

Received: November 2020; Accepted: November 2020; Published online: 17 December 2020

Abstract: Introduction: Many reports have stated that patients admitted for COVID-19 may also suffer from cardiovascular diseases, suggesting cardiovascular involvement in COVID-19. Since there is direct association between electrocardiography (ECG) data and the prognosis of cardiovascular disease, a systematic literature review was performed in the present study to address this association and make a conclusive agreement on the early diagnostic and prognostic values of ECG in patients with COVID-19. Methods: Electronic databases including PubMed, Scopus, Web of Science, Science Direct, Ovid, Embase, and Google Scholar were searched for “COVID-19” and “ECG” using all their equivalents and similar terms as search words. Afterwards, the records were limited to English articles and irrelevant documents, as well as articles that reported drug-induced cardiac dysfunction or patients with previous history of cardiovascular complications were excluded. Results: Overall, 31 articles with 2379 patients were found and used for qualitative data extraction. Findings showed that there is a significant association between COVID-19 infection and ECG findings. Also, ST-segment changes, T wave inversions, QT prolongation, and atrial fibrillation were found to be early indicators of cardiac involvement of COVID-19, which were associated with worse outcomes. Conclusion: It is recommended to use ECG as a valuable diagnostic and prognostic tool for cardiac evaluation of patients with COVID-19.

Keywords: COVID-19; Heart Diseases; Heart Injuries; Electrocardiography; Prognosis

Cite this article as: Nemati R, Ganjoo M, Jadidi F, Tanha A, Baghbani R. Electrocardiography in Early Diagnosis of Cardiovascular Complications of COVID-19; a Systematic Literature Review. Arch Acad Emerg Med. 2021; 9(1): e10.

1. Introduction

Coronavirus Disease 2019 (COVID-19) pandemic started from Wuhan, China in 2019 (1). Coronavirus can cause serious damage to the liver, kidneys, nervous system, lungs, etc. in humans (2-5). Although the lungs are the main target of the virus causing COVID-1, the virus may also affect the heart (6). Although the effects of coronavirus infection on the circulatory system have not been fully understood, it is thought that the new coronavirus may exacerbate the problems of patients with heart failure (7). In addition, there are many reports of high rates of acute heart injury, arrhythmia (irregular heartbeat), hypotension, and tachycardia and other cardiovascular diseases among patients admitted to the intensive care unit due to COVID-19 (8). Overall, by 15 November 2020, 53.7 million confirmed cases and 1.3 million deaths have been reported to WHO (9). Coronavirus aggravates cardiac complications in patients with cardiovascular disease, such that mortality rates of about 10.5% have been observed in patients with cardiovascular diseases (10).

According to recent reports, most patients admitted for COVID-19 have cardiovascular or cerebrovascular diseases. Findings have shown that myocardial injury is associated with adverse prognosis. On the other hand, recent evidence has suggested cardiovascular involvement in COVID-19. There is also a correlation between electrocardiography (ECG) data and the severity of cardiovascular diseases, and clinical outcomes such as death. Therefore, it is suggested

*Corresponding Author: Reza Baghbani; Department of Medical Emergencies, School of Allied Medical Sciences, Bushehr University of Medical Sciences, Bushehr, Iran. Postal code: 7518790077, Tel: +77-3345224, E-mail: R.baghbani1216@gmail.com.
that ECG can be considered as an important diagnostic tool in the early diagnosis of cardiovascular complications, particularly in patients with COVID-19 infection (11). Moreover, ECG changes, as the typical sign of cardiac injury, may reflect a cardiac abnormality in patients with COVID-19, and may also add important prognostic information (12). Accordingly, it is thought that the risk of mortality and cardiovascular comorbidities can be predicted in patients with COVID-19 by evaluating ECG data and markers of myocardial injury (13).

This study may not completely include or reflect the ECG findings of all the reported cases with COVID-19; however, the main aim of this study was to emphasize the cardiac complications due to novel coronavirus disease and the necessity and importance of ECG findings as a prognostic marker. The aim of this study was to determine whether performing an ECG on presentation to hospital has diagnostic value or can provide additional prognostic information, specifically regarding severity of the disease or death outcome, or not. The results of this review may provide a conclusive statement on the value of ECG in patients with COVID-19 infection.

2. Methods

2.1. Study search and inclusion criteria

In the present study, a systematic literature review was performed in Medline via PubMed, Scopus, Web of Science, Science Direct, Ovid, Embase, and Google Scholar to investigate the predictive role or diagnostic value of ECG in patients with COVID-19 infection. For this purpose, “Electrocardiography” and “COVID-19” with all their equivalents and different written forms as key terms were searched in the PubMed as follows: (Electrocardiogram OR ECG OR electrocardiography) AND (Coronavirus OR Coronavirus Disease 2019 OR COVID-19 OR COVID 19 OR SARS-CoV-2 OR COVID OR Corona). To minimize the risk of bias, no strict inclusion criteria were applied and almost all relevant documents were included for data synthesis. First, the search was limited to English articles, and then, review articles, book chapters, letters, and conference papers were excluded. In the Scopus, ECG with all its similar terms was searched in the title, keyword, and abstract. Then, Covid-19 was searched within the results. Afterwards, irrelevant articles were excluded from further evaluation. Chloroquine-induced cardiac complications or other drug-induced ECG variations were excluded and only ECG changes due to coronavirus infection were enrolled for further assessment. Also, reports of patients with documented underlying cardiovascular (CV) comorbidities, coronary artery disease (CAD), or cardiac complications were excluded from additional assessment. The search was independently performed by authors, and any disagreement between the authors in each step was resolved by other authors through repeating the search. PRISMA checklist 2009, which is a valid protocol for performing systematic reviews, was used for study design and in the article selection process (14). According to this protocol, the study was designed to answer the question “can ECG predict the outcomes of patients with COVID-19 and what are the early and frequent alterations found in ECG?”. To follow this protocol, all ECG findings were noted and described.

2.2. Risk of bias assessment

Systematic reviews only rely on the data reported by other studies; hence, the risk of bias in the included studies should be assessed in reporting systematic reviews. Accordingly, in the present systematic review, the risk of bias was evaluated based on the guideline of Cochrane assessing method for observational studies (15). According to this method, (−) showed high risk of bias, whereas (+) showed low, and (?) indicated unclear risk of bias.

2.3. Data synthesis and the variables

All necessary information for data extraction, including the first author’s name, study type, publication date, and number of patients, as well as their sex and mean age were extracted and summarized in Table 1. Furthermore, as the main outcome, ECG results were collected and used for qualitative data description.

3. Results

Literature search was performed on August 2020. Of the 641 articles found in database search, 343 were in the PubMed, 271 were in Scopus, and 27 were in other databases. Also, 2 additional articles were found through reference list search of the included articles. After exclusion of irrelevant articles, a total of 31 related articles were found, 2 of which were retrospective, 3 were cross-sectional, 2 were case control, one was a prospective cohort, and 23 were case reports. The process of article selection for final evaluation is demonstrated in Figure 1. Overall, 2379 patients were enrolled via the 31 included articles, wherein 1575 were male, and 804 were female. All of the articles were published in 2020. The age group of patients varied between 8 to 92 years. The length of follow up in all studies was during hospitalization (2 weeks). The result of risk of bias assessment for the included studies is presented in Figure 3. Demographic information and the most important findings of the included articles are shown in Table 1. According to reports, many patients with COVID-19 had abnormal ECG, including atrial fibrillation, ST-T segment changes, tachycardia, bradycardia, hypertension, atrial premature contractions, intraventricular block, and right bundle branch block (16, 17). It was also demonstrated that mean QTc (410.8 ± 24.3 msec vs. 394.6 ± 20.3 msec, p < 0.001), median QTd (47.52 vs. 46.5) and Tpe/QTc (0.19 ± 0.02 vs.
Evidence also indicated that abnormal ECG in patients with cardiomyocyte involvement in these patients (18). Clinical Tpe/QTc increased in patients with COVID-19, indicating reported that several ECG indicators such as QTc, QTd, and cardiac complications of these patients. Moreover, studies increased in patients with COVID-19, indicating cardiomyocyte involvement in these patients (18). Clinical evidence also indicated that abnormal ECG in patients with COVID-19 may reflect a wide range of cardiovascular complications, and these patients may be at higher risk of death (16, 17). Recent data have shown that myocarditis and acute cardiac injury are common presentations, observed in almost one fifth of patients with COVID-19, with overall 50% survival rate, suggesting the necessity of performing ECG in cases of COVID-19 (29-31). Impaired ventricular function in young patients and children also indicates that the clinicians should be aware of the cardiac involvement in suspected cases of COVID-19 (33). The results of studies also demonstrated that myocardial dysfunction may be a direct manifestation of COVID-19, since cardiac complications were also evident in patients with no previous history of cardiovascular disease (22). Recent data have shown that coronavirus can also affect the small or microvascular vessels and the large coronary arteries even in healthy individuals with no history of cardiovascular diseases. Findings have previously shown that hydroxychloroquine, chloroquine, and azithromycin were also associated with QTc prolongation, but epidemiological data revealed that unlike drug-induced arrhythmias, which are temporary, cardiovascular diseases due to coronavirus may lead to fatal cardiac dysfunction (51, 52). Also, impaired left- and right-ventricular functions were found to be significantly associated with high mortality among patients with COVID-19 (53). Consistent with these findings, the results of an animal study showed that coronavirus infection can lead to sudden cardiac death by increasing ventricular vulnerability in the absence of severe clinical signs of congestive heart failure (54).

Although several studies have shown that vaccination against the Influenza virus can reduce the risk of myocardial infarction, yet there is no information on the mechanistic association between coronary virus and cardiac dysfunctions (55). Animal studies on SARS-CoV have previously shown a connection between virus-induced pulmonary infections and myocardial disease (43). These data showed that SARS-CoV-2 probably has a direct effect on myocardial ion channels (56), while recent data suggested that the etiology of cardiac dysfunction due to SARS-CoV-2 seems to be multifactorial and cannot be through direct damage by the virus, and it is probably due to the response of the host’s immune system to the viral infection or excessive cytokine release (33).

Consistent with these findings, clinical data have also suggested that myocardial injury is probably one of the systemic complications of the new coronavirus (23). Also, T-cell dysregulation, microvascular damage, hypotension and hypoxia-induced myocardial injury are considered as other most probable mechanisms for cardiac injury due to COVID-19 (57). Also, ECG changes in the severe stages of COVID-19 have been found to be the consequences of virus-induced hypoxia and inflammatory damage (12, 26).

The major limitation of this review is lack of enough

4. Discussion

Findings indicated that ST-elevation, bradycardia, atrial fibrillation, left ventricular ejection fraction, and T-wave inversion could be a possible predictor of worse outcome of COVID-19 (26). The results of many studies indicate that infectious diseases cause changes in the ECG, which can indicate cardiovascular damage in these patients (45-50). During the SARS pandemic, a study by Tak - Sun et al. (2004) showed that pneumo-mediastinum complication in SARS can be a possible cause of chest pain and ECG changes (45). The results of Yu et al. study (2006) also indicated that cardiovascular complications including hypotension and tachycardia were common in patients with SARS (46). Also, the results of a 24-hour ECG study of patients with diphtheria showed that many arrhythmias were recorded in all patients (47). In a meta-analysis on Chagas disease, Rojas et al. (2018) also concluded that many changes and arrhythmias such as right bundle branch block (RBBB), left anterior fascicular block (LAFB), atrioventricular (AV) block, atrial fibrillation (AF), and Flutter are observed in the disease. Also, the prevalence of ECG changes in children is the same as in adults (48). Also, studies on other diseases such as hemorrhagic fever with renal syndrome (49) and Lyme disease(50) show the high importance of ECG findings in the diagnosis and cardiac complications of these patients. Moreover, studies reported that several ECG indicators such as QTc, QTd, and Tpe/QTc increased in patients with COVID-19, indicating cardiomyocyte involvement in these patients (18). Clinical evidence also indicated that abnormal ECG in patients with COVID-19 may reflect a wide range of cardiovascular complications, and these patients may be at higher risk of death (16, 17). Recent data have shown that myocarditis and acute cardiac injury are common presentations, observed in almost one fifth of patients with COVID-19, with overall 50% survival rate, suggesting the necessity of performing ECG in cases of COVID-19 (29-31). Impaired ventricular function in young patients and children also indicates that the clinicians should be aware of the cardiac involvement in suspected cases of COVID-19 (33). The results of studies also demonstrated that myocardial dysfunction may be a direct manifestation of COVID-19, since cardiac complications were also evident in patients with no previous history of cardiovascular disease (22). Recent data have shown that coronavirus can also affect the small or microvascular vessels and the large coronary arteries even in healthy individuals with no history of cardiovascular diseases. Findings have previously shown that hydroxychloroquine, chloroquine, and azithromycin were also associated with QTc prolongation, but epidemiological data revealed that unlike drug-induced arrhythmias, which are temporary, cardiovascular diseases due to coronavirus may lead to fatal cardiac dysfunction (51, 52). Also, impaired left- and right-ventricular functions were found to be significantly associated with high mortality among patients with COVID-19 (53). Consistent with these findings, the results of an animal study showed that coronavirus infection can lead to sudden cardiac death by increasing ventricular vulnerability in the absence of severe clinical signs of congestive heart failure (54). Although several studies have shown that vaccination against the Influenza virus can reduce the risk of myocardial infarction, yet there is no information on the mechanistic association between coronavirus and cardiac dysfunctions (55). Animal studies on SARS-CoV have previously shown a connection between virus-induced pulmonary infections and myocardial disease (43). These data showed that SARS-CoV-2 probably has a direct effect on myocardial ion channels (56), while recent data suggested that the etiology of cardiac dysfunction due to SARS-CoV-2 seems to be multifactorial and cannot be through direct damage by the virus, and it is probably due to the response of the host’s immune system to the viral infection or excessive cytokine release (33).

Consistent with these findings, clinical data have also suggested that myocardial injury is probably one of the systemic complications of the new coronavirus (23). Also, T-cell dysregulation, microvascular damage, hypotension and hypoxia-induced myocardial injury are considered as other most probable mechanisms for cardiac injury due to COVID-19 (57). Also, ECG changes in the severe stages of COVID-19 have been found to be the consequences of virus-induced hypoxia and inflammatory damage (12, 26).

The major limitation of this review is lack of enough

4. Discussion

Findings indicated that ST-elevation, bradycardia, atrial fibrillation, left ventricular ejection fraction, and T-wave inversion could be a possible predictor of worse outcome of COVID-19 (26). The results of many studies indicate that infectious diseases cause changes in the ECG, which can indicate cardiovascular damage in these patients (45-50). During the SARS pandemic, a study by Tak - Sun et al. (2004) showed that pneumo-mediastinum complication in SARS can be a possible cause of chest pain and ECG changes (45). The results of Yu et al. study (2006) also indicated that cardiovascular complications including hypotension and tachycardia were common in patients with SARS (46). Also, the results of a 24-hour ECG study of patients with diphtheria showed that many arrhythmias were recorded in all patients (47). In a meta-analysis on Chagas disease, Rojas et al. (2018) also concluded that many changes and arrhythmias such as right bundle branch block (RBBB), left anterior fascicular block (LAFB), atrioventricular (AV) block, atrial fibrillation (AF), and Flutter are observed in the disease. Also, the prevalence of ECG changes in children is the same as in adults (48). Also, studies on other diseases such as hemorrhagic fever with renal syndrome (49) and Lyme disease(50) show the high importance of ECG findings in the diagnosis and cardiac complications of these patients. Moreover, studies reported that several ECG indicators such as QTc, QTd, and Tpe/QTc increased in patients with COVID-19, indicating cardiomyocyte involvement in these patients (18). Clinical evidence also indicated that abnormal ECG in patients with COVID-19 may reflect a wide range of cardiovascular complications, and these patients may be at higher risk of death (16, 17). Recent data have shown that myocarditis and acute cardiac injury are common presentations, observed in almost one fifth of patients with COVID-19, with overall 50% survival rate, suggesting the necessity of performing ECG in cases of COVID-19 (29-31). Impaired ventricular function in young patients and children also indicates that the clinicians should be aware of the cardiac involvement in suspected cases of COVID-19 (33). The results of studies also demonstrated that myocardial dysfunction may be a direct manifestation of COVID-19, since cardiac complications were also evident in patients with no previous history of cardiovascular disease (22). Recent data have shown that coronavirus can also affect the small or microvascular vessels and the large coronary arteries even in healthy individuals with no history of cardiovascular diseases. Findings have previously shown that hydroxychloroquine, chloroquine, and azithromycin were also associated with QTc prolongation, but epidemiological data revealed that unlike drug-induced arrhythmias, which are temporary, cardiovascular diseases due to coronavirus may lead to fatal cardiac dysfunction (51, 52). Also, impaired left- and right-ventricular functions were found to be significantly associated with high mortality among patients with COVID-19 (53). Consistent with these findings, the results of an animal study showed that coronavirus infection can lead to sudden cardiac death by increasing ventricular vulnerability in the absence of severe clinical signs of congestive heart failure (54). Although several studies have shown that vaccination against the Influenza virus can reduce the risk of myocardial infarction, yet there is no information on the mechanistic association between coronavirus and cardiac dysfunctions (55). Animal studies on SARS-CoV have previously shown a connection between virus-induced pulmonary infections and myocardial disease (43). These data showed that SARS-CoV-2 probably has a direct effect on myocardial ion channels (56), while recent data suggested that the etiology of cardiac dysfunction due to SARS-CoV-2 seems to be multifactorial and cannot be through direct damage by the virus, and it is probably due to the response of the host ’ s immune system to the viral infection or excessive cytokine release (33).

Consistent with these findings, clinical data have also suggested that myocardial injury is probably one of the systemic complications of the new coronavirus (23). Also, T-cell dysregulation, microvascular damage, hypotension and hypoxia-induced myocardial injury are considered as other most probable mechanisms for cardiac injury due to COVID-19 (57). Also, ECG changes in the severe stages of COVID-19 have been found to be the consequences of virus-induced hypoxia and inflammatory damage (12, 26).

The major limitation of this review is lack of enough
population-based evidences on the diagnostic value of ECG in complementary and cost-effective diagnosis of COVID-19 infection, since COVID-19 pandemic crisis has affected the priority of the global health system. On the other hand, these results may not be sufficient to reach a conclusive statement about the diagnostic and prognostic values of ECG, because it is not long since this pandemic has emerged; however, findings of this study may encourage clinicians and health practitioners to consider ECG in patients with COVID-19. Clinical data regarding ECG characteristics of patients with COVID-19 is limited. Therefore, further research and clinical observation of these patients is critical to clarify the importance and prognostic value of ECG characteristics in predicting morbidity and mortality.

COVID-19 has been proven to be the leading cause of acute coronary syndrome, myocarditis, and heart failure in both the pediatric and adults (35, 40, 41, 43). Also, it has been demonstrated that cardiomyopathy is a frequent finding in pregnant women with COVID-19 (44, 58). According to the ECG results of a large prospective study, more than half of all suspected cases of COVID-19 showed cardiac complications (24). A growing body of clinical data has shown that COVID-19 may be associated with a high rate of cardiac diseases, leading to a high rate of mortality. Altogether, clinical evidence suggested that ST-segment elevation and T wave inversions, in the absence of other cardiovascular risk factors such as cardiac troponin, can be interpreted as early signs of COVID-19–related myocarditis, suggesting the necessity of early and rapid ECG testing in suspected cases of COVID-19 to prevent severe cardiovascular complications and death (34).

5. Conclusion

In sum, the results of studies demonstrated that COVID-19 can directly or indirectly lead to heart complications even in the absence of other cardiovascular risk factors. Also, it was found that dynamic ECG changes, particularly left and right ventricular dysfunction, ST-segment elevation, and T wave inversions, may reflect different cardiac injuries in patients with COVID-19, which are associated with poor prognosis in these cases.

6. Declarations

6.1. Acknowledgment

None.

6.2. Author contributions

All authors of this study have contributed to data collection, data analysis and manuscript writing.

6.3. Funding

None.

6.4. Conflict of interest

There is no conflict of interest.

References

1. Zhu H, Wei L, Niu P. The novel coronavirus outbreak in Wuhan, China. Global Health Research and Policy. 2020;5(1):1-3.
2. Kang S, Peng W, Zhu Y, Lu S, Zhou M, Lin W, et al. Recent Progress in understanding 2019 novel coronavirus associated with human respiratory disease: detection, mechanism and treatment. International Journal of Antimicrobial Agents. 2020;55(5):105950.
3. Qian J-Y, Wang B, Liu B-C. Acute kidney injury in the 2019 novel coronavirus disease. Kidney Diseases. 2020;6(5):318-23.
4. Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, et al. Clinical Features of COVID-19-Related Liver Functional Abnormality. Clin Gastroenterol Hepatol. 2020;18(7):1561-6.
5. Dorche MS, Huot P, Osherov M, Wen D, Saveriano A, Giacomini P, et al. Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic. Journal of the Neurological Sciences. 2020;417:117085.
6. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovascular research. 2020;116(10):1666-87.
7. DeFilippis EM, Reza N, Donald E, Givetiz MM, Lindenfeld J, Jessup M. Considerations for Heart Failure Care During the COVID-19 Pandemic. JACC Heart failure. 2020;8(8):681-91.
8. Ben Gal T, Ben Avraham B, Abu-Hazira M, Frigerio M, Crespo-Leiro MG, Oppelaar AM, et al. The consequences of the COVID-19 pandemic for self-care in patients supported with a left ventricular assist device. European journal of heart failure. 2020;22(6):933-6.
9. Organization WH. COVID-19 weekly epidemiological update, 17 November 2020. 2020.
10. Dan S, Pant M, Upadhyay SK. The Case Fatality Rate in COVID-19 Patients With Cardiovascular Disease: Global Health Challenge and Paradigm in the Current Pandemic. Current Pharmacology Reports. 2020;1-10.
11. Churchill TW, Bertrand PB, Bernard S, Namasiyam M, Churchill J, Crousillat D, et al. Echocardiographic Features of COVID-19 Illness and Association with Cardiac Biomarkers. Journal of the American Society of Echocar-
10. Deng Q, Hu B, Chen Y, Tang J, Liu Q, Zhou S, et al. Characteristic Electrocardiographic Manifestations in Patients With COVID-19. The Canadian journal of cardiology. 2020;36(6):966 e1- e4.

11. Shi S, Qin M, Cai Y, Liu T, Shen B, Yang E, et al. Characteristics and clinical significance of myocardial injury in patients with the severe coronavirus disease 2019. European heart journal. 2020;41(22):e2070-9.

12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.

13. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ. 2011;343:d5928.

14. Angeli F, Spanevello A, De Ponti R, Visca D, Marazzato J, Palmiotto G, et al. Electrocardiographic features of patients with COVID-19 pneumonia. European journal of internal medicine. 2020;78:101-6.

15. McCullough SA, Goyal P, Krishnan U, Choi JJ, Safford MM, Okin PM. Electrocardiographic Findings in Coronavirus Disease-19: Insights on Mortality and Underlying Myocardial Processes. Journal of cardiac failure. 2020;26(7):626-32.

16. Amaratunga EA, Corwin DS, Moran L, Snyder R. Bradycardia in Patients With COVID-19: A Calm Before the Storm? Cureus. 2020;12(6):e8599.

17. Gill GS, Vlancanich R, Mehta N, Chaturvedi M, Papolos A. Spectrum of Cardiac Involvement in COVID-19. Cureus. 2020;12(6):e8638.

18. Tedeschi D, Rizzi A, Biscaglia S, Tumscitz C. Acute myocardial infarction and large coronary thrombosis in a patient with COVID-19. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions. 2020.

19. Doyen D, Moceri P, Dureux D, Dellamonica J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet. 2020;395(10235):1516.

20. Kim IC, Kim JY, Kim HA, Han S. COVID-19-related myocarditis in a 21-year-old female patient. European heart journal. 2020;41(19):1859.

21. Ibrahim-Ortiz A, Carreras-Mora J, Sionis A, Pamiès J, Montriel J, Tauron M. Fulminant myocarditis due to COVID-19. Rev Esp Cardiol (Engl Ed). 2020;73(6):503-4.

22. Czigici AY, Zencirkiran Agus H, Yildiz M. COVID-19 myocarditis: It should be kept in mind in today’s conditions. The American journal of emergency medicine. 2020;38(7):1547 e5- e6.

23. Oberweis ML, Codreanu A, Boehm W, Olivier D, Pierron C, Tsobo C, et al. Pediatric Life-Threatening Coronavirus Disease 2019 With Myocarditis. The Pediatric infectious disease journal. 2020;39(7):e147-e9.

24. Loghin C, Chauhan S, Lawless SM. Pseudo-Acute Myocardial Infarction in a Young COVID-19 Patient. JACC Case reports. 2020;2(9):1284-8.

25. Hussain H, Fadel A, Alwaeli H, Guardiola V. Coronavirus (COVID-19) Fulminant Myopericarditis and Acute Respiratory Distress Syndrome (ARDS) in a Middle-Aged Male Patient. Cureus. 2020;12(6):e8808.

26. Juthani P, Bhoywani R, Gupta N. Coronavirus Disease 2019 (COVID-19) Manifestation as Acute Myocardial Infarction in a Young, Healthy Male. Case reports in infectious diseases. 2020;2020:8864985.

27. Ong E, Castro-Dominguez Y, Brennan J, Oen-Hsiao J. COVID-19 complicated by ST-segment elevation myocardial infarction in a 29-year-old patient. Catheterization...
tion and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions. 2020.

38. Rehman M, Gondal A, Rehman NU. Atypical Manifestation of COVID-19-Induced Myocarditis. Cureus. 2020;12(6):e8685.

39. van den Heuvel FMA, Vos JL, Koop Y, van Dijk APJ, Duijnhouwer AL, de Mast Q, et al. Cardiac function in relation to myocardial injury in hospitalised patients with COVID-19. Netherlands heart journal: monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation. 2020;28(7-8):410-7.

40. Asif T, Ali Z. Transient ST Segment Elevation in Two Patients with COVID-19 and a Normal Transthoracic Echocardiogram. European journal of case reports in internal medicine. 2020;7(5):001672.

41. Zeng JH, Liu YX, Yuan J, Wang FX, Wu WB, Li JX, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020.

42. Stefanini GG, Montorfano M, Trabattoni D, Andreini D, Ferrante G, Ancona M, et al. ST-Elevation Myocardial Infarction in Patients With COVID-19: Clinical and Angiographic Outcomes. Circulation. 2020;141(25):2113-6.

43. Trogen B, Gonzalez FJ, Shust GF. COVID-19-Associated Myocarditis in an Adolescent. The Pediatric infectious disease journal. 2020;39(8):e204-e5.

44. Juusela A, Nazir M, Gimovsky M. Two cases of coronavirus 2019-related cardiomyopathy in pregnancy. American journal of obstetrics & gynecology MFM. 2020;2(2):100113.

45. Tak-Sun T, Kin-Lam T, Loretta YC, Arthur CW, Kwok-Keung C, et al. Occult pneumomediastinum in a SARS patient presenting as recurrent chest pain and acute ECG changes mimicking acute coronary syndrome. Respirology (Carlton, Vic). 2004;9(2):271-3.

46. Yu C, Wong RS, Wu E, Kong S, Wong J, Yip GW, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgraduate Medical Journal. 2006;82(964):140-4.

47. Bethell DB, Dung NM, Loan HT, Minh LTN, Dung NQ, Day NP, et al. Prognostic value of electrocardiographic monitoring of patients with severe diphtheria. Clinical Infectious Diseases. 1995;20(5):1259-65.

48. Rojas LZ, Glisic M, Pletsch-Borba L, Echeverría LE, Bramer WM, Bano A, et al. Electrocardiographic abnormalities in Chagas disease in the general population: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases. 2018;12(6):e0006567.

49. Puljiz I, Kuzman I, Markotič A, Turčinov D, Matić M, Makek N. Electrocardiographic changes in patients with haemorrhagic fever with renal syndrome. Scandinavian Journal of Infectious Diseases. 2005;37(8):594-8.

50. Woolf PK, Lorsung EM, Edwards KS, Li KI, Kanengiser SI, Ruddy RM, et al. Electrocardiographic findings in children with Lyme disease. Pediatric Emergency Care. 1991;7(6):334-6.

51. Hsia BC, Greige N, Quiroz JA, Khokhar AS, Daily J, Di Biase L, et al. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. Journal of interventional cardiac electrophysiology: an international journal of arrhythmias and pacing. 2020.

52. Tuncer T, Karaci M, Boga A, Durmaz H, Guven S. QT interval evaluation associated with the use of hydroxychloroquine with combined use of azithromycin among hospitalised children positive for coronavirus disease 2019. Cardiology in the young. 2020:1-4.

53. Rath D, Petersen-Uribe A, Avdiu A, Witzel K, Jaeger P, Zdanye M, et al. Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection. Clinical research in cardiology: official journal of the German Cardiac Society. 2020.

54. Alexander LK, Keene BW, Yount BL, Geratz JD, Small JD, Baric RS. ECG changes after rabbit coronavirus infection. Journal of electrocardiology. 1999;32(1):21-32.

55. MacIntyre CR, Mahimbo A, Moa AM, Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart. 2016;102(24):1953-6.

56. Pasqualletto MC, Corrado A, Secco E, Gracey F, Rigo F. Transient Type 1 Brugada Pattern without Ongoing Fever during COVID-19 Pneumonia. European journal of case reports in internal medicine. 2020;7(2):271-3.

57. Kim HN, Lee JH, Park HS, Yang DH, Jang SY, Bae MH, et al. A Case of COVID-19 with Acute Myocardial Infarction and Cardiogenic Shock. Journal of Korean medical science. 2020;35(27):e258.

58. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. Jama. 2020.
### Table 1: General information of included studies

| No. | Author               | Country   | Study type type | No. of Patients | Mean age | Male/Female ratio | ECG findings                                                                 |
|-----|----------------------|-----------|-----------------|-----------------|----------|-------------------|------------------------------------------------------------------------------|
| 1   | Angeli F (16)        | Italy     | CCS             | 50              | 64       | 36/14             | Atrial fibrillation, ST-T changes, tachy-brady syndrome                      |
| 2   | McCullough SA (17)   | USA       | RS              | 756             | 63.3     | 476/280           | Atrial prematurity contractions, intraventricular block, repolarization, right bundle branch block |
| 3   | Kochav SM (25)       | USA       | CR              | 4               | 56, 64, 70, 76 | 3/1             | Atrioventricular dissociation, high-grade heart block, atrial fibrillation, T wave inversions and QT prolongation, sinus tachycardia with left bundle branch block |
| 4   | Vidovich MI (21)     | USA       | CR              | 1               | 61       | 1/-               | Brugada-like ECG pattern with normal coronary arteries                       |
| 5   | Vera-Pineda R (22)   | Mexico    | CR              | 4               | 26, 64, 66, 76 | 4/-              | Ventricular dysfunction                                                      |
| 6   | Amaratunga EA (26)   | USA       | CR              | 4               | 55, 60, 73, 78 | 2/2              | Bradycardia                                                                 |
| 7   | He J (12)            | China     | CR              | 2               | 66, 70   | 1/1               | Atrioventricular block, ST-segment elevation, ventricular tachycardia        |
| 8   | Oztürk F (18)        | Turkey    | CCS             | 51              | 49.2     | 29/22             | High QTc, QTd, and Tpe/QTc                                                  |
| 9   | Gill GS (27)         | USA       | CR              | 2               | 34, 65   | -/2               | ST elevations, Low amplitude, PR segment depressions                         |
| 10  | van de Poll SWE (20) | Netherlands | CR            | 2               | 40, 58   | 2/-               | Sinus rhythm                                                                |
| 11  | Tedeschi D (28)      | Italy     | CR              | 1               | 60       | 1/-               | ST-elevation, myocardial infarction                                          |
| 12  | Doyen D (29)         | France    | CR              | 1               | 69       | 1/-               | Left ventricular hypertrophy, diffuse inverted T waves                       |
| 13  | Kim IC (30)          | Korea     | CR              | 1               | 21       | -/1               | Severe left ventricular systolic dysfunction                                 |
| 14  | Irabien-Ortiz Á (31) | Spain     | CR              | 1               | 59       | -/1               | Concentric hypertrophy, Reduced intraventricular volumes, ST-segment elevation, PR-segment depression, low voltages |
| 15  | Cizgici AY (32)      | Turkey    | CR              | 1               | 78       | 1/-               | Atrial fibrillation and ST elevation                                        |
| 16  | Oberweis ML (33)     | Belgium   | CR              | 1               | 8        | 1/-               | LVEF                                                                        |
| 17  | Pavri BB (19)        | USA       | CSS             | 75              | 67       | 37/38             | Paradoxical prolongation (abnormal PR interval) or lack of shortening        |
| 18  | Loghin C (34)        | USA       | CR              | 1               | 29       | 1/-               | ST-segment elevations                                                       |
| 19  | Hussain H (35)       | USA       | CR              | 1               | 51       | 1/-               | Global left ventricular hypokinesia, reduced LVEF                           |
| 20  | Juthani P (36)       | USA       | CR              | 1               | 29       | 1/-               | ST-elevations                                                               |
| 21  | Ong E (37)           | USA       | CR              | 1               | 29       | 1/-               | ST-elevations                                                               |
| 22  | Rehman M (38)        | USA       | CR              | 1               | 39       | 1/-               | ST elevations, and T-wave inversion                                         |
| 23  | Vera-Pineda R (22)   | Mexico    | CR              | 4               | 26, 64, 66, 76 | 4/-              | LVEF                                                                        |
| 24  | van den Heuvel FMA (39) | Netherlands | CSS             | 51              | 63       | 40/11             | LVEF                                                                        |
| 25  | Asif T (40)          | USA       | CR              | 2               | 64, 71   | 1/1               | ST elevation, non-specific T wave changes                                   |
| 26  | Zeng JH (41)         | China     | CR              | 1               | 63       | 1/-               | LVEF                                                                        |
| 27  | Deng Q (23)          | China     | RS              | 112             | 65 (24-92) | 57/55            | Pericardial effusion                                                        |
| 28  | Stefanini GG (42)    | Italy     | CSS             | 28              | 68       | 20/8              | ST-elevation                                                               |
| 29  | Dweck MR (24)        | USA       | PCS             | 1216            | 62       | 851/365           | LVEF, RVEF                                                                 |
| 30  | Trogen B (43)        | USA       | CR              | 1               | 17       | 1/-               | Tachycardia and T-wave inversion                                            |
| 31  | Jussela A (44)       | USA       | CR              | 2               | 26, 45   | -/2               | LVEF hypokinesis                                                           |

**CCS:** case control study; **RS:** retrospective study; **CR:** case report; **CSS:** cross-sectional study; **PCS:** prospective cohort study; **ECG:** electrocardiography; **LVEF:** Left ventricular ejection fraction; **RVEF:** Right ventricular ejection fraction.
Figure 1: Article selection process.
Figure 2: Frequency of electrocardiography complications among patients with COVID-19 infection.
Figure 3: Risk of bias assessment for included articles based on Cochrane risk of bias evaluation method.